ReviewNeuroscience insights2023
Role of Citicoline in Patients With Mild Cognitive Impairment.
Review in Neuroscience insights, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 2 syntheses or guidelines pooled it, 25 citations in OpenAlex.
- Preclinical studies of conditioned medium of hypoxic-preconditioned mesenchymal stem cell/hypMSC-CM for ischemic stroke: A systematic review.Open veterinary journal · 2026Pooled it
- The efficacy of different doses of citicoline in improving the prognosis of patients with acute ischemic stroke based on network meta-analysis.Frontiers in pharmacology · 2025Pooled it
- Diagnosis and management of subjects with mild cognitive impairment in clinical practice: an Italian delphi consensus study.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026Article
- The Real-World Early Neuroprotective Effects of Oral Citicoline Combination in Prodromal Dementia.Nutrients · 2026Observational
- The effect of citicoline administration on visual function improvement in stroke patients at Prof. Dr. Chairuddin Panusunan Lubis Hospital, University of Sumatera Utara, and affiliated network hospitals.Frontiers in medicine · 2026Article
- Pharmacological Management of Mild Cognitive Impairment: From Symptomatic Treatment to Disease Modification-A Narrative Review.NeuroSci · 2025Review
- Fatty liver reexamined choline and mitochondrial toxin amelioration.World journal of biological chemistry · 2025Review
- The impact of citicoline on brain mitochondrial dysfunction induced in rats after head irradiation.Scientific reports · 2025Article
- The role of neuro-supportive substances of natural origin in neurological conditions-A literature-based formulators' perspective.Frontiers in neurology · 2025Article
- Real-life management of patients with mild cognitive impairment: an Italian survey.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2024Article
- Memory Recovery Effect of a New Bioactive Innovative Combination in Rats with Experimental Dementia.Antioxidants (Basel, Switzerland) · 2023Article
- Citicoline May Prevent Cognitive Decline in Patients with Cerebrovascular Disease.Clinical interventions in aging · 2023Observational
- Current perspectives on prevention of vascular cognitive impairment and promotion of vascular brain health.Expert review of neurotherapeuticsReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The term mild cognitive impairment (MCI) defines an intermediate state between normal aging and dementia. Vascular cognitive impairment refers to a decline in cognitive function that is caused by or associated with vascular disease and comprises all the spectrum of cognitive impairments, from MCI of vascular origin to vascular dementia. One of the available treatments for cognitive impairment is cytidine diphosphate-choline (CDP-Choline), or citicoline. The objective of the present manuscript is to provide complete evidence about the efficacy of citicoline for MCI, especially of vascular origin, but also due to other neurodegenerative disorders. Citicoline is a pharmaceutical product constituted by the combination of 2 natural molecules (cytidine and choline) and is marketed as a food supplement. It has been proposed to provide neuroprotective effects through diverse mechanisms of action. Taking into account the available literature, citicoline has shown a consistent improvement in cognitive function in patients with MCI, especially of vascular origin. Moreover, it provides beneficial effects on vascular, Alzheimer, and mixed dementias, stroke sequelae, intracerebral hemorrhages, traumatic brain injuries, and neurodegenerative diseases. Long-term treatment with citicoline has also been demonstrated to be well-tolerated and has not been associated with severe adverse events. Citicoline is a safe, well-tolerated, and promising agent with evidenced neuroprotective properties.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.